
Zoetis Faces Shareholder Lawsuit Over Alleged Misleading Performance Data
Investors who held Zoetis Inc. securities between January 2025 and May 2026 have until July 27 to join a class action lawsuit. The litigation claims the animal health giant concealed weakening demand for its core products, including the canine pain treatment Librela, causing significant stock price drops.

























